UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Diabetes, obesity & metabolism, 2008-05, Vol.10 (5), p.376-386

2008

Volltextzugriff (PDF)

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [ 177 Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer

Korean Journal of Radiology, 2024, 25(2), , pp.179-188

2024

Volltextzugriff (PDF)

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Diabetes, obesity & metabolism, 2019-04, Vol.21 (4), p.883-892

2019

Volltextzugriff (PDF)

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Diabetes, obesity & metabolism, 2015-07, Vol.17 (7), p.630-638

2015

Volltextzugriff (PDF)

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.523-532

2011

Volltextzugriff (PDF)

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.186-190

2016

Volltextzugriff (PDF)

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1513-1520

2017

Volltextzugriff (PDF)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Diabetes, obesity & metabolism, 2011-06, Vol.13 (6), p.567-576

2011

Volltextzugriff (PDF)

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Diabetes, obesity & metabolism, 2015-05, Vol.17 (5), p.487-494

2015

Volltextzugriff (PDF)

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Diabetes, obesity & metabolism, 2016-12, Vol.18 (12), p.1253-1262

2016

Volltextzugriff (PDF)

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1045-1050

2017

Volltextzugriff (PDF)

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Oncotarget, 2017-01, Vol.8 (2), p.3581-3590

2017

Volltextzugriff (PDF)

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2011-09, Vol.13 (9), p.850-858

2011

Volltextzugriff (PDF)

Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage

World journal of gastroenterology : WJG, 2008-01, Vol.14 (3), p.474-478

2008

Volltextzugriff (PDF)

Saxagliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes

Cardiology in review, 2010-07, Vol.18 (4), p.213-217

2010

Volltextzugriff (PDF)

Management of Dry Eye Toxicity After Treatment With 177 Lu-PSMA-617 Radioligand Therapy

Practical radiation oncology, 2024-07, Vol.14 (4), p.301

2024

Volltextzugriff (PDF)

177 Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment

Current radiopharmaceuticals, 2024, Vol.17 (4), p.356

2024

Volltextzugriff (PDF)

Effect of glutamine on serum interleukin-8 and tumor necrosis factor-alpha levels in patients with severe pancreatitis

Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008-01, Vol.28 (1), p.129

2008

Volltextzugriff (PDF)

Efficacy of the dipeptide N(2)-L-Alanyl-L-glutamine in traumatic patients admitted to the ICU: a prospective, randomized, double-blind, multicentre study

Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral, 2012-01, Vol.27 (1), p.116-122

2012

Volltextzugriff (PDF)

Nephroprotection with saxagliptin

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2015-11, Vol.32 (6)

2015

Volltextzugriff (PDF)

Pathogenesis, diagnosis and treatment of hepatic encephalopathies in patients with liver cirrhosis

Likars'ka sprava, 2014-11 (11), p.39

2014

Volltextzugriff (PDF)

Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease

Biology of blood and marrow transplantation, 2009-12, Vol.15 (12), p.1609-1619

2009

Volltextzugriff (PDF)

Effect of early enriched parenteral alanyl-glutamine on heat shock protein 70 (HSP70) expression in critical patients

Zhongguo wei zhong bing ji jiu yi xue, 2007-08, Vol.19 (8), p.481

2007

Volltextzugriff (PDF)

The prospective study on application of parenteral nutrition with alanyl-glutamine dipeptide in chemotherapy of gastrointestinal neoplasms patients

Ai zheng = Aizheng = Chinese journal of cancer, 2006-08, Vol.25 (8), p.1044

2006

Volltextzugriff (PDF)

Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report

Scandinavian journal of urology and nephrology. Supplement, 1984, Vol.79, p.103

1984

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

KollektionSage Journals

Nur zeigenGeprüft (Peer-Review)

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(20)

Publikationsform

Artikel
(41)

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(41)
Dipeptides - Therapeutic Use
(36)
Male
(36)
Middle Aged
(34)
Female
(28)
Adult
(25)
Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Adamantane - Analogs & Derivatives
(13)
Adamantane - Therapeutic Use
(13)
Diabetes Mellitus, Type 2 - Drug Therapy
(12)
Double-Blind Method
(12)
Dipeptides - Adverse Effects
(11)
Endocrinology & Metabolism
(11)
Treatment Outcome
(11)
Diabetes
(10)
Dipeptidyl-Peptidase Iv Inhibitors - Therapeutic Use
(9)
Blood Pressure - Drug Effects
(8)
Adolescent
(7)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [ 177 Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open‐label randomized controlled study (the SMART study)

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study

Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage

Saxagliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes

Management of Dry Eye Toxicity After Treatment With 177 Lu-PSMA-617 Radioligand Therapy

177 Lu-PSMA-617 Radioligand Treatment in Elderly Patients with Metastatic Castration-resistant Prostate Cancer: Therapeutic Efficacy and Safety Assessment

Effect of glutamine on serum interleukin-8 and tumor necrosis factor-alpha levels in patients with severe pancreatitis

Efficacy of the dipeptide N(2)-L-Alanyl-L-glutamine in traumatic patients admitted to the ICU: a prospective, randomized, double-blind, multicentre study

Nephroprotection with saxagliptin

Pathogenesis, diagnosis and treatment of hepatic encephalopathies in patients with liver cirrhosis

Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease

Effect of early enriched parenteral alanyl-glutamine on heat shock protein 70 (HSP70) expression in critical patients

The prospective study on application of parenteral nutrition with alanyl-glutamine dipeptide in chemotherapy of gastrointestinal neoplasms patients

Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report

Aktive Filter

Suchergebnisse filtern